[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oct-angiography\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oct-angiography":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,59],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":39,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":5},"100617275","optimal-strategy-to-correct-stent-underexpansion-in-resistant-lesions-100617275",false,"NCT07316504","Optimal Strategy to Correct Stent underexpAnsion in Resistant Lesions","OSCAR","Inclusion criteria :\n\n* Patient who have undergone coronary angiography with ISR, defined as ≥50% reduction of the diameter of the intrastent lumen occurring ≥ 6 months after stent implantation\n* And with a suspicion of stent under-expansion on angiography, possibly assisted by a stent enhancement technique\n* The reference diameter of the target vessel must be ≥2.5 mm and ≤5.0 mm.\n* Coronary flow must be TIMI 3\n* Ability to cross the lesion with the OCT catheter (possibly after predilatation with a balloon up to 2 mm)\n* Patient affiliated to the French National Health Insurance\n\nExclusion criteria :\n\n* Heart failure with NYHA III or IV (or cardiogenic shock)\n* LVEF \\\u003C20%\n* Chronic renal failure with clearance \\\u003C30mL\u002Fmn according to CKD\n* Pregnant or breast-feeding women\n* Patient with a condition\u002Fcomorbidity that could reduce compliance with the protocol, including pre-specified study follow-up\n* Patient participating in another ongoing medical study evaluating a pharmacological or biological agent or medical device, unless authorized by the concomitant protocol.\n* Patient unable to tolerate double antiaggregation (i.e., aspirin and clopidogrel or prasugrel or ticagrelor) for at least 6 months.\n* Possible or defined thrombus (by angiography or endovascular imaging) in the target vessel.","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","Percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) accounts for 5-10% of PCI. ISR may be linked to mechanical complications mainly under-expansion (UE), neointimal hyperplasia and\u002For neoatherosclerosis. International guidelines recommends non-compliant and very-high-pressure balloons, which lead to sub-optimal angiographic and clinical results. Recently, observational studies have suggested the feasibility and safety of intravascular lithotripsy (IVL) in UE treatment. There are no prospective randomised controlled studies comparing intravascular lithotripsy with balloons in ISR with UE.",[26,27,28,29,30,31,32,33,34,35,36,37,38],"Coronary Angioplasty","Restenosis","Lithotripsy","Restenosis of Coronary Artery Stent","Angioplasty, Transluminal, Percutaneous Coronary","Percutaneous Coronary Intervention (PCI)","OCT Angiography","Optical Coherence Tomography (OCT)","Intravascular Lithotripsy; Rotational Atherectomy; OFDI","Intravascular Lithotripsy","Coronary Artery Disease","Coronary Artery Disease (CAD)","Coronary Stent Restenosis",[40,41,42,43,44,45,46],"restenosis","underexpansion","intrastent restenosis","randomized clinical trial","intravascular lithotripsy","baloon PCI","Percutaneous coronary intervention","RECRUITING","2025-12-18",{"date":50,"type":51},"2026-01-05","ACTUAL",{"date":53,"type":51},"2025-10-22",{"date":55,"type":20},"2031-09",{"name":57,"class":58},"University Hospital, Clermont-Ferrand","OTHER",{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100595770","coronary-evaluation-and-guided-lesion-exploration-using-photon-counting-ct-and-intracoronary-imaging-techniques-100595770","NCT07036770","Coronary Evaluation And Guided Lesion Exploration Using Photon-counting CT and Intracoronary Imaging Techniques","C-EAGLE","Inclusion criteria:\n\nParticipants eligible for inclusion in this study must meet all of the following criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.\n2. At least 18 years of age at the time of signing the Informed Consent Form (ICF).\n3. Patients presenting with suspected acute coronary syndrome (UA or NSTEMI) or chronic coronary syndrome (stable angina or silent ischemia).\n\nExclusion criteria:\n\nParticipants eligible for this study must not meet any of the following criteria:\n\n1. Patients presenting with STEMI.\n2. Haemodynamically unstable patients.\n3. Unstable ventricular arrhythmias.\n4. Killip class III-IV heart failure.\n5. Creatinine clearance \\\u003C30 ml\u002Fmin\u002F1.73 m2 (as calculated by CKD-EPI formula 2009 for estimated GFR) and not on dialysis. Note: patients dependent on long-term dialysis are eligible for enrolment irrespective of their creatinine clearance levels.\n6. Severe coronary vessel tortuosity.\n7. Subject has known hypersensitivity to radiocontrast dye or that cannot be adequately pre-medicated.\n8. Female who is pregnant or breast-feeding.",{"count":67,"type":20},100,"OBSERVATIONAL","This study evaluates the diagnostic accuracy and limitations of photon-counting computed tomography (PCCT) in characterizing coronary plaque, with comparisons to optical coherence tomography (OCT) and intravascular ultrasound (IVUS). The objective is to assess whether cardiac ultra-high resolution (UHR) PCCT -with its improved spatial resolution and superior soft tissue contrast relative to conventional CT- can serve as a reliable, non-invasive alternative for coronary plaque assessment and support clinical decision-making. A total of 100 patients with either acute or chronic coronary syndrome will be enrolled, including 40 individuals with suspected in-stent restenosis and 10 patients one year post-percutaneous coronary intervention (PCI) for chronic total occlusion (CTO). All participants will undergo invasive coronary angiography based on current European Society of Cardiology guidelines. Cardiac PCCT imaging will be conducted shortly before the angiographic procedure, accompanied by invasive OCT evaluation. Additionally, a subgroup of 10 patients will undergo both OCT and IVUS, allowing for direct comparison across imaging modalities. OCT, regarded as the gold standard for plaque characterization, offers near-histological resolution for identifying plaque features, while IVUS is particularly effective in evaluating plaque burden and volume.",[36,32,71],"CT",[73],"PCCT","2025-06-16",{"date":76,"type":51},"2025-06-25",{"date":74,"type":20},{"date":79,"type":20},"2027-05-31",{"name":81,"class":58},"Universitaire Ziekenhuizen KU Leuven",1]